⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BCYC News
Form 8-K
sec.gov
BCYC
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
businesswire.com
BCYC
Form 8-K
sec.gov
BCYC
Form 8-K
sec.gov
BCYC
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
businesswire.com
BCYC
Form 8-K
sec.gov
BCYC
Form 8-K
sec.gov
BCYC
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
businesswire.com
BCYC
Form 8-K
sec.gov
BCYC
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
businesswire.com
BCYC